Mark J. Ratain to Cyclophosphamide
This is a "connection" page, showing publications Mark J. Ratain has written about Cyclophosphamide.
Connection Strength
0.139
-
Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours. Br J Cancer. 2002 Feb 12; 86(4):534-9.
Score: 0.049
-
Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study. J Natl Cancer Inst. 1993 Aug 18; 85(16):1319-26.
Score: 0.027
-
Response to high dose cyclophosphamide with GM-CSF in Merkel cell tumor. Ann Oncol. 1991 Jul; 2(7):522-3.
Score: 0.024
-
A limited sampling strategy for cyclophosphamide pharmacokinetics. Cancer Res. 1989 Jun 01; 49(11):3129-33.
Score: 0.020
-
Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642). Clin Cancer Res. 1995 Jul; 1(7):699-704.
Score: 0.008
-
Conservative management of primary cervical lymphoma using combination chemotherapy: a case report. Gynecol Oncol. 1989 Dec; 35(3):391-4.
Score: 0.005
-
Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide. J Clin Oncol. 1988 Jul; 6(7):1192-6.
Score: 0.005